N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 1, 2013, Pages 312-317

  Wang, Zhiping ^a   Liu, Yuangang ^a   Takahashi, Maho ^b   Van Hook, Kathryn ^a   Kampa Schittenhelm, Kerstin M ^c   Sheppard, Brett C ^a   Sears, Rosalie C ^b   Stork, Philip J S ^b   Lopez, Charles D ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN ASPP2; RAF PROTEIN; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL AGING; CELL MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

APOPTOSIS REGULATORY PROTEINS; CELL AGING; DIMERIZATION; FIBROBLASTS; HCT116 CELLS; HUMANS; KERATINOCYTES; MAP KINASE SIGNALING SYSTEM; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; PLASMIDS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; RNA, SMALL INTERFERING;

EID: 84871946420     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1201514110     Document Type: Article

References (50)

1. Kampa KM, Bonin M, Lopez CD (2009) New insights into the expanding complexity of the tumor suppressor ASPP2. Cell Cycle 8(18):2871-2876.
2. Vives V, et al. (2006) ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev 20(10):1262-1267. (Pubitemid 43727587)
3. Kampa KM, et al. (2009) Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci USA 106(11):4390-4395.
4. Bergamaschi D, et al. (2004) ASPP1 and ASPP2: Common activators of p53 family members. Mol Cell Biol 24(3):1341-1350. (Pubitemid 38112194)
5. Gorina S, Pavletich NP (1996) Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274(5289):1001-1005. (Pubitemid 26398426)
6. Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S (1994) Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci USA 91(13):6098-6102. (Pubitemid 24188290)
7. Samuels-Lev Y, et al. (2001) ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8(4):781-794. (Pubitemid 33030212)
8. Lopez CD, et al. (2000) Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53. Mol Cell Biol 20(21):8018-8025.
9. Chen D, Padiernos E, Ding F, Lossos IS, Lopez CD (2005) Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene. Cell Death Differ 12(4):358-368. (Pubitemid 40520687)
10. Zhu Z, et al. (2005) Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function. J Biol Chem 280(41):34473-34480. (Pubitemid 41504576)
11. Cong W, et al. (2010) ASPP2 regulates epithelial cell polarity through the PAR complex. Curr Biol 20(15):1408-1414.
12. Sottocornola R, et al. (2010) ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. Dev Cell 19(1):126-137.
13. Wang X, et al. (2010) SUMO-modified nuclear cyclin D1 bypasses Ras-induced senescence. Cell Death Differ 18(2):304-314.
14. Liu C, et al. (2011) PP1 Cooperates with ASPP2 to Dephosphoryate and Activate TAZ. J Biol Chem 18:5558-5566.
15. Wang Y, et al. (2012) Autophagic activity dictates the cellular response to oncogenic RAS. Proc Natl Acad Sci USA 109(33):13325-13330.
16. Campisi J, d'Adda di Fagagna F (2007) Cellular senescence: When bad things happen to good cells. Nat Rev Mol Cell Biol 8(9):729-740. (Pubitemid 47312822)
17. Ewald JA, Desotelle JA, Wilding G, Jarrard DF (2010) Therapy-induced senescence in cancer. J Natl Cancer Inst 102(20):1536-1546.
18. Michaloglou C, et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436(7051):720-724. (Pubitemid 41117276)
19. Chen Z, et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436(7051):725-730. (Pubitemid 41117277)
20. Bartkova J, et al. (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444(7119):633-637. (Pubitemid 44864442)
21. Collado M, SerranoM(2010) Senescence in tumours: Evidence from mice and humans. Nat Rev Cancer 10(1):51-57.
22. Lin AW, et al. (1998) Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12(19):3008-3019. (Pubitemid 28469303)
23. Zhu J, Woods D, McMahon M, Bishop JM (1998) Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12(19):2997-3007. (Pubitemid 28469302)
24. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88(5):593-602. (Pubitemid 27152402)
25. Sarkisian CJ, et al. (2007) Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9(5):493-505. (Pubitemid 46696530)
26. Maurer G, Tarkowski B, Baccarini M (2011) Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 30(32):3477-3488.
27. Wellbrock C, Karasarides M, Marais R (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5(11):875-885. (Pubitemid 39486539)
28. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7(4):295-308. (Pubitemid 46480970)
29. Bergamaschi D, et al. (2003) iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33(2):162-167. (Pubitemid 36177067)
30. Trigiante G, Lu X (2006) ASPP [corrected] and cancer. Nat Rev Cancer 6(3):217-226.
31. Rotem S, Katz C, Friedler A (2007) Insights into the structure and protein-protein interactions of the pro-apoptotic protein ASPP2. Biochem Soc Trans 35(Pt 5):966-969. (Pubitemid 350206406)
32. Tidow H, Andreeva A, Rutherford TJ, Fersht AR (2007) Solution structure of ASPP2 N-terminal domain (N-ASPP2) reveals a ubiquitin-like fold. J Mol Biol 371(4):948-958. (Pubitemid 47101808)
33. Slee EA, et al. (2004) The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene 23(56):9007-9016. (Pubitemid 40013067)
34. Naumovski L, Cleary ML (1996) The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol Cell Biol 16(7):3884-3892. (Pubitemid 26199908)
35. Takahashi N, et al. (2004) Expression of 53BP2 and ASPP2 proteins from TP53BP2 gene by alternative splicing. Biochem Biophys Res Commun 315(2):434-438. (Pubitemid 38183124)
36. Sachdev S, Hoffmann A, Hannink M (1998) Nuclear localization of IkappaB alpha is mediated by the second ankyrin repeat: The IkappaB alpha ankyrin repeats define a novel class of cis-acting nuclear import sequences. Mol Cell Biol 18(5):2524-2534. (Pubitemid 28183422)
37. Bunz F, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282(5393):1497-1501. (Pubitemid 28538613)
38. Weber CK, Slupsky JR, Kalmes HA, Rapp UR (2001) Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res 61(9):3595-3598. (Pubitemid 32694968)
39. Diaz B, et al. (1997) Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling. Mol Cell Biol 17(8):4509-4516. (Pubitemid 27318127)
40. King AJ, et al. (1998) The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396(6707):180-183. (Pubitemid 28523621)
41. Mason CS, et al. (1999) Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18(8):2137-2148. (Pubitemid 29179171)
42. Wang W, et al. (2002) Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 22(10):3389-3403. (Pubitemid 34453979)
43. Swami M (2009) Apoptosis: Dodging death. Nat Rev Cancer 9:316.
44. McCarthy N (2010) Cell polarity: ASPP2 gets a polarity complex. Nat Rev Cancer 10(8): 528.
45. Rotem S, et al. (2008) The structure and interactions of the proline-rich domain of ASPP2. J Biol Chem 283(27):18990-18999.
46. Mishra S, Smolik SM, Forte MA, Stork PJ (2005) Ras-independent activation of ERK signaling via the torso receptor tyrosine kinase is mediated by Rap1. Curr Biol 15(4):366-370. (Pubitemid 40263371)
47. Helps NR, Barker HM, Elledge SJ, Cohen PT (1995) Protein phosphatase 1 interacts with p53BP2, a protein which binds to the tumour suppressor p53. FEBS Lett 377(3):295-300. (Pubitemid 26025716)
48. Castro ME, et al. (2008) PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis 29(3):491-499.
49. Garnett MJ, Rana S, Paterson H, Barford D, Marais R (2005) Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20(6):963-969. (Pubitemid 41814884)
50. Dimri GP, Itahana K, Acosta M, Campisi J (2000) Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol 20(1):273-285. (Pubitemid 30002569)